{"prompt": "['Amended Clinical Trial Protocol NO 03', '18-Apr-2018', 'ACT14656', 'Version number: 1', '5', 'STUDY OBJECTIVES', '5.1', 'PRIMARY', 'Assess the effects of SAR407899 on coronary vasomotor function using CFR in patients', 'with microvascular angina and/or persistent stable angina despite angiographically', 'successful PCI.', '5.2', 'SECONDARY', 'Assess the effects of SAR407899 in patients with microvascular angina and/or persistent', 'stable angina despite angiographically successful PCI using SAQ-PL.', 'Assess the safety of SAR407899 in patients with microvascular angina and/or persistent', 'stable angina despite angiographically successful PCI with a focus on identified risks such', 'as hypotension and orthostatic hypotension.', 'Assess SAR407899 plasma concentrations in microvascular angina patients and/or', 'persistent stable angina despite angiographically successful PCI.', 'Property of the Sanofi Group - strictly confidential', 'Page 36', '(electronic 4.0)']['Amended Clinical Trial Protocol NO 03', '18-Apr-2018', 'ACT14656', 'Version number: 1', '6', 'STUDY DESIGN', '6.1', 'DESCRIPTION OF THE STUDY', 'A Phase 2a, multi-center, randomized with 1:1 ratio, double-blind, placebo-controlled parallel', 'group study with weekly titration up to maintenance dose, based on individual patient tolerability,', 'particularly symptomatic or asymptomatic BP decreases.', '6.2', 'DURATION OF STUDY PARTICIPATION', '6.2.1 Duration of study participation for each patient', 'Screening: up to 4 weeks before the first dosing (Day -28 to Day -1) and up to 6 weeks in', 'patients diagnosed with MVA and stable angina without previous PCI who did not have a', 'coronary artery angiography or CCTA in the previous 24 months but between 24 months', 'and 5 years prior to screening and requiring CCTA in this screening period.', 'Titration phase: 3 weeks.', 'Maintenance phase: 1 week.', 'Total duration of treatment: 4 weeks (including titration).', 'Follow-up: 1 week.', 'Total study duration: 9 weeks (=2 days) and up to 11 weeks (+/- 2 days) in patients', 'requiring CCTA in screening period.', '6.2.2 Determination of end of clinical trial (all patients)', 'The end of the clinical trial is defined as the day when the last patient completes her/his last visit', 'planned in the protocol.', '6.3', 'INTERIM ANALYSIS', 'A safety review with a DMC meeting will start as soon as the first 19 patients will have been', 'randomized and have finished the first week of treatment. Additional analyses for safety may be', 'performed in this study.', 'Refer to Section 11.5 and to Section 6.4.1 for details on interim analyses.', 'Property of the Sanofi Group - strictly confidential', 'Page 37', '(electronic 4.0)']['Amended Clinical Trial Protocol NO 03', '18-Apr-2018', 'ACT14656', 'Version number: 1', '6.4', 'STUDY COMMITTEES', '6.4.1 Data Monitoring Committee', 'A Data Monitoring Committee (DMC) will be charged with monitoring the safety of the patients', 'participating in this clinical trial. This committee is comprised of externally-based individuals', 'with expertise in the diseases under study, biostatistics, or clinical research. The DMC will review', 'all serious adverse events (SAEs), death, and adverse events of special interest (AESIs), in due', 'time. The DMC will give appropriate recommendations to the Sponsor on safety aspects during', 'the conduct of the study, if needed. The DMC is justified by the early stage of development of', 'SAR407899 that has not gathered safety information in patients with microvascular angina or', 'persistent angina despite angiographically successful PCI and the identified risk of hypotension.', 'The DMC responsibilities and the data review processes are fully described in the DMC charter', 'that will be developed prior to study start.', 'In the above capacities, the DMC is advisory to the Sponsor. The Sponsor is responsible for', 'promptly reviewing and for taking into account in a timely manner the recommendations of the', 'DMC in terms of trial continuation with or without alterations or of potential trial termination.', 'Following DMC review of the safety data (of the first 19 patients who will have completed first', 'week after randomization) and their recommendations, the Sponsor may have to adjust titration', 'schedules and dosing regimen.', 'Property of the Sanofi Group - strictly confidential', 'Page 38', '(electronic 4.0)']\n\n###\n\n", "completion": "END"}